NCT00541281
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer treatment 2 completed NCT02985021
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies treatment 2 terminated NCT02966587
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 2 withdrawn NCT02184533
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer treatment 1 completed NCT01093183
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer treatment 1 / 2 terminated NCT01498978
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 2 completed NCT04516707
Evaluation of Tolerance and Efficacy Retrospective Data of XOFIGO No drug interventions Not Available Not Available completed NCT01949337
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer treatment 3 active_not_recruiting NCT01468532
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 1 / 2 completed NCT00936975
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases No drug interventions diagnostic 2 completed NCT01050842
Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer treatment 0 completed NCT02499835
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer treatment 1 / 2 completed NCT02169063
Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer No drug interventions diagnostic Not Available withdrawn NCT01685125
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 2 unknown_status NCT02312557
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide treatment 2 active_not_recruiting NCT01807065
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer treatment 2 completed NCT01522820
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors treatment 1 completed NCT02844582
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 2 terminated NCT01338792
Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer treatment 2 completed NCT02429804
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer diagnostic 1 terminated NCT01519414
Tivantinib in Treating Patients With Metastatic Prostate Cancer treatment 2 completed NCT00040755
BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy treatment 2 completed NCT02370355
Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer No drug interventions Not Available Not Available terminated NCT01145508
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 2 terminated NCT01469338
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel supportive_care 2 terminated NCT03122743
Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer No drug interventions Not Available Not Available completed NCT03154190
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer No drug interventions health_services_research Not Available unknown_status NCT02853097
Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients No drug interventions Not Available Not Available terminated NCT02215161
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer treatment 2 terminated NCT02491411
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel treatment Not Available terminated NCT00513071
AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy treatment 2 completed NCT00016107
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer treatment 2 completed NCT01913015
Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 1 terminated NCT00570700
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer treatment 2 completed NCT02516670
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer treatment 2 terminated NCT02881242
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer treatment 2 active_not_recruiting NCT00486642
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy treatment 2 completed NCT01253642
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel treatment 2 terminated NCT01174199
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer treatment 1 terminated NCT02567396
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction treatment 1 withdrawn NCT02012296
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer treatment 1 / 2 completed NCT03979339
Feasibility of a New Technology for Isolating Circulating Tumour Cells No drug interventions other Not Available unknown_status NCT01267266
Saracatinib in Treating Patients With Prostate Cancer treatment 2 terminated NCT01270880
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy treatment 2 completed NCT01240629
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 1 / 2 completed NCT01503229
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 2 completed NCT01953640
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy No drug interventions Not Available Not Available active_not_recruiting NCT01848067
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer treatment 1 / 2 completed NCT01812668
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer treatment Not Available completed NCT01533246
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer treatment 2 completed NCT01802346
Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer No drug interventions supportive_care Not Available active_not_recruiting NCT00110214
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy treatment 3 completed NCT02159950
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 2 completed NCT01866423
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 2 terminated NCT01026623
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer treatment 1 / 2 completed NCT01833208
Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T No drug interventions treatment Not Available completed